Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02824575 · ClinicalTrials.gov registry record · Phase 1
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
A Phase 1 study, sponsored by Montefiore Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02824575 is a Phase 1 study that was terminated before completion, run by Montefiore Medical Center. The registered enrollment target is 28 participants.
The verdict
NCT02824575, a Phase 1 study, was terminated before completion, sponsored by Montefiore Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of rebastinib when combined with antitubulin therapy with paclitaxel or eribulin in patients with advanced breast cancer.
Interventions
- DRUG Paclitaxel
- DRUG Eribulin Mesylate
- DRUG Rebastinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-07 |
| Est. Completion | 2021-12-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02824575
The ClinicalTrials.gov registry entry for NCT02824575 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Paclitaxel is the first listed.
NCT02824575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02824575 about?
NCT02824575 is a clinical study titled "Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer". The purpose of this study is to determine the safety and tolerability of rebastinib when combined with antitubulin therapy with paclitaxel or eribulin in patients with advanced breast cancer.
What is the current status of trial NCT02824575?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-07. Estimated completion is 2021-12-27.
What interventions are being tested in trial NCT02824575?
The interventions under investigation include: Paclitaxel (DRUG), Eribulin Mesylate (DRUG), Rebastinib (DRUG).
Who is sponsoring clinical trial NCT02824575?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.